Helistat Absorbable Collagen Hemostatic Agent and Helitene Absorbable Collagen Hemostatic Agent- Fibrillar Form
Integra LifeSciences Corporation · Decision date Sep 18, 2026
What did the FDA decide?
This 30-Day Notice for PMA supplement P850010/S119 covers Integra LifeSciences Corporation's Helistat and Helitene absorbable collagen hemostatic agents. The stated change is the installation and qualification of a new Water for Injection pretreatment, generation, storage, and distribution system.
The supplement type is a process change involving manufacturer, sterilizer, packager, or supplier. The FDA decision field shows OK30, dated 2026-09-18. The notice does not describe clinical testing, safety outcomes, or effectiveness data. Specific details about equipment location, validation protocols, or acceptance criteria are absent from the supplied fields.
FDA approval order statement
installation and qualification of a new Water for Injection (WFI) pretreatment, generation, storage, and distribution system
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Sep 18, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P850010/S119
- Regulatory pathway
- PMA supplement
- Applicant
- Integra LifeSciences Corporation
- Product code
- LMF
- Decision code
- OK30
- Decision date
- Sep 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, collagen based.
- Applicant
- Integra LifeSciences Corporation
- Product code
- LMF
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P850010. Subsequent supplements may change the device or its indications.
FDA decision timeline
P850010 · Original PMA
HELISTAT(TM) ABSORBABLE COLLAGEN HEMOSTATIC SPONGE
P850010/S119 received
Application receipt date recorded by FDA.
P850010/S119 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P850010. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P850010
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Integra LifeSciences Corporation | PMA approval | Nov 8, 1985 | FDA |
Explore the linked device profile
Other records with product code LMF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| C.R. Bard, Inc. | PMA supplement | Sep 29, 2026 | FDA | |
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA | |
SURGIFOAM Absorbable Gelatin SpongeP990004/S080 | Ferrosan Meidcal Devices A/S | PMA supplement | Sep 18, 2026 | FDA |
| Ferrosan Meidcal Devices A/S | PMA approval | Sep 30, 1999 | FDA | |
COLLASTATP810006 | Integra LifeSciences Corporation | PMA approval | Dec 10, 1981 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Integra LifeSciences Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 311 Enterprise Dr., Plainsboro, NJ, 08540
Sources and methodology
- Original FDA record: P850010/S119
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

